Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-1|1|362|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-2|1|472|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-3|1|549|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-4|1|569|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-5|1|590|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-6|1|620|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-7|1|639|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-8|1|641|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-9|1|644|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-10|1|645|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-11|1|695|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-12|1|701|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-13|1|705|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-14|1|707|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-15|1|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-16|1|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-17|1|721|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-18|1|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-19|1|730|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCVS TO LUNG.|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-20|1|731|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-21|1|743|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-22|1|746|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-23|1|753|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-24|1|757|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-25|1|761|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-26|1|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-27|1|785|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-28|1|787|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-29|1|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-30|1|788|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-31|1|801|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-32|1|817|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Trunk missing,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-33|1|822|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-34|1|822|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-35|1|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-36|1|836|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-37|1|841|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-38|1|843|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-39|1|845|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-40|1|846|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-41|1|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-42|1|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-43|1|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-44|1|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-45|1|862|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-46|1|865|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-47|1|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-48|1|869|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-49|1|876|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-50|1|876|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-51|1|877|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-52|1|879|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-53|1|880|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-54|1|881|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-55|1|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ Eyes and head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-56|1|885|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-57|1|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-58|1|891|Neoplasia unclassified|Central nervous system among nervous system|TNXS/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-59|1|898|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-60|1|899|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-61|1|901|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-62|1|904|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-63|1|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-64|1|905|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-65|1|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-66|1|912|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-67|1|913|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-68|1|914|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ nape of neck.|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-69|1|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-70|1|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-71|1|920|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-72|1|921|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to visc. pleura of esoph.,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-73|1|921|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-74|1|925|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-75|1|927|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO INTERCOSTAL MUSCLES.|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-76|1|928|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-77|1|929|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-78|1|932|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-79|1|932|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-80|1|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-81|1|933|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-82|1|937|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ with infilt. of pancreas. Metastases Heart|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-83|1|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-84|1|940|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-85|1|943|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ pelvic region.|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-86|1|945|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-87|1|947|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-88|1|953|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-89|1|953|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ adj. to lumbar vert. Metastases  tcvs invad. spinal ganglion. Metastases  Muscle tcvs invad. muscle & bone of lumbar spine.|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-90|1|954|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-91|1|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-92|1|960|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-93|1|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-94|1|963|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-95|1|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-96|1|966|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-97|1|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-98|1|967|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-99|1|970|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-100|1|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-101|1|971|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-102|1|977|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-103|1|978|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-104|1|981|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-105|1|985|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-106|1|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-107|1|986|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-108|1|991|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-109|1|992|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-110|1|998|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-111|1|1002|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-112|1|1004|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-113|1|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-114|1|1008|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MPNE/  acute,MPATH: 212 - inflammation|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-115|1|1016|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-116|1|1021|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-117|1|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-118|1|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-119|1|1027|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-120|1|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-121|1|1034|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-122|1|1039|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-123|1|1040|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-124|1|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-125|1|1044|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ preputial angiosarc.|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-126|1|1045|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-127|1|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-128|1|1060|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-129|1|1066|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-130|1|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-131|1|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-132|1|1073|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-133|1|1079|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-134|1|1079|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-135|1|1081|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-136|1|1082|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-137|1|1086|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-138|1|1086|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-139|1|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-140|1|1088|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-141|1|1089|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-142|1|1089|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-143|1|1092|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to visc. & pariet. pleura. Metastases  Muscle trac to intercostal muscles.,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-144|1|1097|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-145|1|1098|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-146|1|1102|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-147|1|1102|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS INVAD. MUSCLE & BONE OF LUMBAR SPINE.|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-148|1|1102|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-149|1|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-150|1|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-151|1|1112|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-152|1|1115|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-153|1|1118|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-154|1|1121|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-155|1|1122|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-156|1|1122|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-157|1|1129|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-158|1|1139|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-159|1|1144|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-160|1|1148|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-161|1|1154|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-162|1|1159|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ sem. vesicles. Metastases  Lung metas. of txac of seminal vesicles to lung.,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-163|1|1160|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-164|1|1162|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-165|1|1163|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-166|1|1166|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-167|1|1169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-168|1|1170|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-169|1|1171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-170|1|1173|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-171|1|1173|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-172|1|1173|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-173|1|1179|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-174|1|1187|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ surr. aorta at base of heart.|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-175|1|1193|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-176|1|1195|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-177|1|1196|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-178|1|1205|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-179|1|1212|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-180|1|1222|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-181|1|1225|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-182|1|1226|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-183|1|1230|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-184|1|1233|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-185|1|1233|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-186|1|1243|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-187|1|1263|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-188|1|1263|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-189|1|1264|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-190|1|1277|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-191|1|1278|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-192|1|1286|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-193|1|1305|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ area of diaph.|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-194|1|1307|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-195|1|1318|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-196|1|1339|n/a|n/a|n/a|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-197|1|1447|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-198|1|1455|Other deterministic changes|Whole body|MCDU/|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-199|1|1458|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-1|n/a,S0|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 872 ± 13 lifespan study|1003-21-1-200|1|1473|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-1|2|220|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-2|2|318|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-3|2|424|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-4|2|446|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-5|2|461|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-6|2|484|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-7|2|492|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-8|2|502|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-9|2|521|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-10|2|523|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-11|2|529|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-12|2|556|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-13|2|567|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-14|2|575|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ vert. of lumbar region. Metastases Lung|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-15|2|577|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-16|2|577|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-17|2|577|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-18|2|577|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-19|2|577|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-20|2|584|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-21|2|584|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-22|2|584|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-23|2|584|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-24|2|584|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-25|2|606|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-26|2|611|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-27|2|614|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-28|2|619|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-29|2|626|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-30|2|641|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-31|2|654|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-32|2|655|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDTC/  Transitional cell,MPATH: 549 - carcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-33|2|666|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-34|2|667|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-35|2|674|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-36|2|680|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-37|2|691|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt. l.n.,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-38|2|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-39|2|698|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-40|2|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-41|2|707|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-42|2|708|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWO: TOGC TO LUNG.|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-43|2|721|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-44|2|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-45|2|739|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-46|2|745|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-47|2|746|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-48|2|761|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-49|2|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-50|2|769|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-51|2|772|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-52|2|773|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-53|2|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-54|2|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-55|2|788|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-56|2|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-57|2|790|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-58|2|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-59|2|793|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to bronch. & pt. l.n. Metastases Heart Metastases  Muscle trac to muscle of rib cage.,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-60|2|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-61|2|813|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. L.N.|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-62|2|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-63|2|837|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-64|2|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-65|2|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-66|2|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-67|2|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-68|2|854|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-69|2|854|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-70|2|861|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-71|2|863|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-72|2|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-73|2|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-74|2|873|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-75|2|878|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWS: TSEC TO MUSCLE OF UPPER JAW.|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-76|2|879|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-77|2|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-78|2|885|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-79|2|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-80|2|889|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to intercostal muscles. Metastases  trac to mediastinum. Metastases  Lymphoret.System trac to pt. l.n., br. l.n.,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-81|2|904|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-82|2|904|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-83|2|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-84|2|912|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-85|2|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-86|2|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-87|2|919|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-88|2|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphoma Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-89|2|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-90|2|931|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF VERT. TO LUNG.|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-91|2|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-92|2|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-93|2|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-94|2|935|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-95|2|935|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ lumbar dorsal.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-96|2|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-97|2|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-98|2|949|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ ear canal. Metastases  Lung mult. metas. from txec of ear canal to lung.,MPATH: 446 - squamous cell carcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-99|2|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-100|2|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-101|2|955|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-102|2|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-103|2|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-104|2|964|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-105|2|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-106|2|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-107|2|969|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-108|2|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-109|2|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-110|2|980|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to mediast. pleura. Metastases Heart, costal muscle, pt. l.n..  Eyes and head/neck missing,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-111|2|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-112|2|988|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-113|2|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-114|2|989|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-115|2|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-116|2|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-117|2|993|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-118|2|995|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-119|2|997|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-120|2|1001|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-121|2|1004|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-122|2|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-123|2|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-124|2|1013|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-125|2|1013|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. L.N.|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-126|2|1018|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-127|2|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-128|2|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-129|2|1026|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-130|2|1030|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWO: TOGC TO LUNG.|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-131|2|1030|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-132|2|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-133|2|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-134|2|1040|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-135|2|1040|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-136|2|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-137|2|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-138|2|1044|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-139|2|1045|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-140|2|1046|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ face.,MPATH: 218 - neoplasm|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-141|2|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-142|2|1052|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-143|2|1053|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-144|2|1054|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-145|2|1057|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-146|2|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-147|2|1059|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-148|2|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-149|2|1063|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-150|2|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-151|2|1078|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-152|2|1079|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-153|2|1088|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-154|2|1094|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-155|2|1095|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-156|2|1097|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-157|2|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-158|2|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-159|2|1115|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tcfs to intercostal muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-160|2|1117|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-161|2|1124|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ dorsal thorax.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-162|2|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-163|2|1132|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-164|2|1134|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-165|2|1135|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-166|2|1157|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-167|2|1159|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-168|2|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-169|2|1165|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-170|2|1167|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-171|2|1174|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-172|2|1177|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-173|2|1177|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-174|2|1188|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-175|2|1191|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-176|2|1191|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-177|2|1199|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-178|2|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-179|2|1203|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-180|2|1205|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tcfs to muscle of pelvic region.|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-181|2|1207|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-182|2|1214|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-183|2|1221|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-184|2|1226|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-185|2|1237|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-186|2|1242|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-187|2|1242|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-188|2|1246|n/a|n/a|n/a|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-189|2|1260|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-190|2|1265|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-191|2|1310|Other deterministic changes|Whole body|MCDU/|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-192|2|1350|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Muscle tsec to muscle of upper jaw.,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-193|2|1362|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-194|2|1411|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-2|n/a,SO|1|100|shamexposed|0|grays|External exposure|code S0 1 fraction 20 m|195 (195 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|190 records survival 820 ± 16 lifespan study|1003-21-2-195|2|1432|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-1|3|91|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-2|3|159|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-3|3|486|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ rt. hind leg - ventral. Metastases  Skin invasion of skin by tcvs on leg.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-4|3|488|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-5|3|582|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-6|3|590|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-7|3|592|Neoplasia unclassified|Other local manifestations and miscellaneus|TSWC: INVASION OF SKIN BY TCVS.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-8|3|619|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-9|3|624|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMVS FROM THIGH TO LUNG.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-10|3|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-11|3|656|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-12|3|657|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-13|3|659|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMVS FROM THIGH TO LUNG.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-14|3|662|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-15|3|670|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-16|3|680|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-17|3|684|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Lymphoret.System to pt. l.n. by tgac.,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-18|3|693|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-19|3|701|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-20|3|716|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ scrotal area.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-21|3|723|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-22|3|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-23|3|737|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-24|3|739|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-25|3|743|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-26|3|746|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-27|3|757|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-28|3|762|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-29|3|764|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCA/ MMCA/ MMCA/ MMCA/  acute,MPATH: 212 - inflammation|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-30|3|765|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-31|3|767|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-32|3|774|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-33|3|775|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Thorax missing,MPATH: 242 - hemangiosarcoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-34|3|779|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-35|3|779|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-36|3|786|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-37|3|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-38|3|788|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-39|3|788|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-40|3|796|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-41|3|796|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-42|3|801|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-43|3|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-44|3|809|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-45|3|815|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ urethral wall.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-46|3|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-47|3|824|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ axillary region.,MPATH: 218 - neoplasm|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-48|3|824|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-49|3|824|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-50|3|826|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  Eye(s) missing Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-51|3|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-52|3|834|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-53|3|835|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-54|3|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-55|3|844|Neoplasia unclassified|Other local manifestations and miscellaneus|TSWC: INVASION OF SKIN BY TCVS ON LEG.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-56|3|846|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-57|3|852|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-58|3|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-59|3|862|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-60|3|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-61|3|875|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-62|3|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-63|3|876|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-64|3|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-65|3|878|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-66|3|880|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-67|3|883|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Skin invasion of skin by tcfs.,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-68|3|883|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-69|3|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-70|3|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-71|3|888|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ scrotum.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-72|3|892|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-73|3|894|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-74|3|898|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-75|3|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to rib cage and diaphragm.,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-76|3|902|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-77|3|904|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. L.N..|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-78|3|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-79|3|906|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to gut l.n.. Metastases Heart Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-80|3|913|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-81|3|915|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-82|3|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-83|3|929|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-84|3|932|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-85|3|935|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-86|3|939|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-87|3|939|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-88|3|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-89|3|941|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. L.N.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-90|3|946|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-91|3|949|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-92|3|949|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-93|3|954|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ adjacent to kidney. Metastases  Muscle trac to muscle of rib cage.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-94|3|955|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle invasion of costal muscle of rib cage by tgac. Metastases Lung Metastases  invasion of nasal turbinates by tgac.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-95|3|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-96|3|962|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle costal muscles by tgac. Metastases Lung|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-97|3|963|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-98|3|966|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-99|3|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-100|3|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-101|3|971|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System pt. l.n. by tgac. Metastases Heart Metastases  trac to visc. pleura, esoph. & pariet. pleura.,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-102|3|972|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-103|3|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-104|3|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-105|3|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-106|3|982|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh muscle. Muscle Metastases Lung tmvs from thigh to lung.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-107|3|985|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-108|3|989|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  trac to pancreas. Metastases  Lymphoret.System trac to pt. l.n..,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-109|3|992|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-110|3|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-111|3|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-112|3|1006|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-113|3|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-114|3|1009|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-115|3|1023|Neoplasia unclassified|Other local manifestations and miscellaneus|TSWC: INVASION OF SKIN BY TCVS.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-116|3|1027|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-117|3|1029|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-118|3|1029|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-119|3|1030|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ lumbar reg. of back. Muscle|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-120|3|1030|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-121|3|1030|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-122|3|1032|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-123|3|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-124|3|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-125|3|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-126|3|1037|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-127|3|1038|Neoplasia unclassified|Other local manifestations and miscellaneus|TSWC: INVASION OF SKIN BY TCVS.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-128|3|1044|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-129|3|1048|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-130|3|1049|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-131|3|1051|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-132|3|1052|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-133|3|1053|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle trac to chest muscle|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-134|3|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-135|3|1061|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-136|3|1062|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-137|3|1067|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-138|3|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-139|3|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-140|3|1072|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-141|3|1072|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-142|3|1075|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-143|3|1076|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-144|3|1079|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-145|3|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-146|3|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-147|3|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Lymphoret.System invasion of pt. l.n. by trac.,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-148|3|1086|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-149|3|1088|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-150|3|1098|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-151|3|1110|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-152|3|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-153|3|1115|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-154|3|1118|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-155|3|1119|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. L.N.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-156|3|1128|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-157|3|1131|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-158|3|1139|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-159|3|1144|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-160|3|1144|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-161|3|1145|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-162|3|1146|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-163|3|1156|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-164|3|1159|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-165|3|1160|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-166|3|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-167|3|1160|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-168|3|1173|Neoplasia malignant|Bloodvessels among cardiovascular system|TDVS/  Urinary bladder|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-169|3|1193|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-170|3|1205|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-171|3|1205|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lymphoret.System trac to pt. l.n. Metastases  Skin tcvs to skin of ing. region. Metastases  Muscle tcvs to skeletal muscle of ing. region.,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-172|3|1209|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-173|3|1212|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-174|3|1212|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-175|3|1222|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases Liver Metastases  Muscle tbos to muscle of thigh. Metastases Lung|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-176|3|1225|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-177|3|1226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-178|3|1229|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-179|3|1236|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-180|3|1237|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-181|3|1238|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-182|3|1241|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-183|3|1244|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ abd. wall. Metastases  spread of tcvs over periton. of kid. & adr. Metastases  Muscle tcvs to muscle of abdominal wall.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-184|3|1251|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-185|3|1254|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-186|3|1261|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Skin invasion of skin by tcvs.,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-187|3|1274|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-188|3|1278|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-189|3|1282|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-190|3|1284|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-191|3|1288|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TO PT. L.N. BY TGAC.|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-192|3|1289|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-193|3|1289|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-194|3|1290|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-195|3|1298|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-196|3|1328|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-197|3|1367|Other deterministic changes|Whole body|MCDU/|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-198|3|1385|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-199|3|1393|n/a|n/a|n/a|
1003-21-3|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 858 ± 14 lifespan study|1003-21-3-200|3|1430|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-1|4|435|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-2|4|443|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-3|4|476|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcutis of tail.|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-4|4|489|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-5|4|523|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-6|4|523|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-7|4|562|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-8|4|564|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF VERT. TO LUNG.|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-9|4|581|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-10|4|624|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-11|4|627|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-12|4|634|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-13|4|659|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-14|4|680|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-15|4|680|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-16|4|687|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-17|4|690|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-18|4|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-19|4|696|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-20|4|696|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-21|4|701|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWC: TCFS TO VISCERAL PERIT. AROUND KID. & GUT WALL.|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-22|4|701|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-23|4|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-24|4|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-25|4|721|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-26|4|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-27|4|729|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-28|4|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-29|4|744|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  Lymphoret.System trac to pt. l.n..,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-30|4|753|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-31|4|754|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-32|4|761|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-33|4|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-34|4|765|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-35|4|767|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-36|4|767|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-37|4|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-38|4|771|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-39|4|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-40|4|784|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart tcfs to heart.,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-41|4|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-42|4|789|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ back of neck.|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-43|4|791|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-44|4|792|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-45|4|801|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-46|4|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-47|4|806|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. BRONCH. L.N..|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-48|4|807|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-49|4|808|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-50|4|809|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-51|4|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-52|4|810|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ ear.,MPATH: 218 - neoplasm|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-53|4|816|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-54|4|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-55|4|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-56|4|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-57|4|824|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-58|4|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-59|4|827|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-60|4|831|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-61|4|834|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-62|4|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-63|4|841|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-64|4|849|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-65|4|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-66|4|852|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-67|4|855|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-68|4|857|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-69|4|866|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-70|4|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-71|4|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/  Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-72|4|870|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-73|4|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Trunk missing,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-74|4|878|Other deterministic changes|Whole body|MCDU/   Thorax and head/neck missing|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-75|4|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-76|4|884|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-77|4|889|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-78|4|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-79|4|892|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-80|4|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-81|4|896|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ adj. to thoracic vert.. Metastases Lung|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-82|4|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-83|4|906|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-84|4|907|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-85|4|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-86|4|911|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum.Enteritis acute,MPATH: 212 - inflammation|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-87|4|918|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt. l.n..,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-88|4|925|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-89|4|934|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  Muscle tbvs to muscle of femur.,MPATH: 242 - hemangiosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-90|4|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-91|4|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-92|4|938|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-93|4|942|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-94|4|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-95|4|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-96|4|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-97|4|945|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-98|4|946|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-99|4|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-100|4|948|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt. bronch. l.n..,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-101|4|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-102|4|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-103|4|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-104|4|956|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-105|4|957|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ thoracic wall. Metastases  Muscle tcfs to rib cage muscles & musc. of abd. wall.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-106|4|960|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-107|4|960|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thoracic spine. Muscle|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-108|4|962|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-109|4|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-110|4|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-111|4|966|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-112|4|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-113|4|971|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-114|4|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-115|4|974|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-116|4|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-117|4|976|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-118|4|981|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-119|4|981|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-120|4|984|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases Liver|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-121|4|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-122|4|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-123|4|995|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-124|4|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-125|4|1003|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-126|4|1008|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. L.N..|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-127|4|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-128|4|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-129|4|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-130|4|1018|Neoplasia unclassified|Other local manifestations and miscellaneus|THWO: TOGC TO LIVER.|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-131|4|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-132|4|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-133|4|1025|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-134|4|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-135|4|1028|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-136|4|1029|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-137|4|1030|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-138|4|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-139|4|1033|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-140|4|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-141|4|1033|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-142|4|1035|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF SPINE TO LUNG.|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-143|4|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-144|4|1037|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCVS OF TAIL TO LUNG.|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-145|4|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-146|4|1040|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-147|4|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-148|4|1045|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-149|4|1058|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ sacral spine. Metastases Lung|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-150|4|1059|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-151|4|1062|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-152|4|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-153|4|1066|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-154|4|1068|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-155|4|1069|Inflammation and/or fibrotic diseases|Heart among cardiovascular system,MA: 0000076 - heart endocardium|MECC/  Chronic valvular endocarditis,MPATH: 214 - chronic inflammation|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-156|4|1079|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ right side of neck,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-157|4|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-158|4|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-159|4|1086|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-160|4|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-161|4|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-162|4|1089|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-163|4|1094|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-164|4|1097|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-165|4|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-166|4|1101|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tcfs to neck muscle and jaw bone.,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-167|4|1102|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-168|4|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-169|4|1107|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ on belly. Metastases  tcfs to visceral perit. around kid. & gut wall.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-170|4|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-171|4|1111|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-172|4|1111|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-173|4|1116|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-174|4|1117|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-175|4|1118|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-176|4|1118|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-177|4|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-178|4|1149|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-179|4|1160|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-180|4|1161|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-181|4|1168|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-182|4|1177|n/a|n/a|n/a|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-183|4|1179|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-184|4|1184|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMTA/  Metritis|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-185|4|1187|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-186|4|1191|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ abdominal region. Metastases  Kidney metas. of tcfs to kidney. Metastases Liver Metastases Lung Metastases Lung Metastases  Muscle metas. of tcfs on diaphragm.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-187|4|1200|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-188|4|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-189|4|1215|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-190|4|1223|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-191|4|1228|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-192|4|1235|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-193|4|1244|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-194|4|1279|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-195|4|1285|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-196|4|1307|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-197|4|1362|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-198|4|1364|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-199|4|1405|Other deterministic changes|Whole body|MCDU/|
1003-21-4|n/a,S4|1|100|gamma-rays Co-60|0.9|grays|External exposure|code S4 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 825± 13 lifespan study|1003-21-4-200|4|1465|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-1|5|386|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-2|5|388|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-3|5|429|Other deterministic changes|Whole body|MCDU/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-4|5|443|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-5|5|470|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-6|5|507|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-7|5|547|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-8|5|571|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-9|5|587|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-10|5|613|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-11|5|620|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-12|5|621|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-13|5|641|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ salivary gland.,MPATH: 549 - carcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-14|5|654|Other deterministic changes|Whole body|MCDU/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-15|5|654|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-16|5|659|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-17|5|663|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-18|5|675|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-19|5|680|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-20|5|686|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ 2 sites in pelvis. Muscle|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-21|5|697|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-22|5|699|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ ear.,MPATH: 218 - neoplasm|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-23|5|713|Neoplasia systemic|Haematolymphatic system|TLML/   Metastases  Lymphoret.System trac to bronch. lns.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-24|5|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-25|5|722|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-26|5|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-27|5|730|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-28|5|757|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-29|5|759|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-30|5|761|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-31|5|764|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-32|5|764|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-33|5|765|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-34|5|765|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-35|5|768|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung tiec of salivary gland to lung.,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-36|5|779|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC METAS TO PT LNS.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-37|5|784|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-38|5|786|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-39|5|787|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-40|5|792|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-41|5|799|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-42|5|811|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-43|5|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-44|5|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-45|5|823|Neoplasia systemic|Haematolymphatic system|TLML/   Metastases Lung|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-46|5|827|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-47|5|829|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-48|5|834|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-49|5|837|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-50|5|837|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ tail muscle with metas to skin of tail.,MPATH: 428 - rhabdomyosarcoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-51|5|839|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-52|5|843|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-53|5|849|Other deterministic changes|Whole body|MCDU/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-54|5|855|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-55|5|865|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-56|5|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-57|5|869|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC METAS TO PT LNS.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-58|5|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-59|5|870|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-60|5|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-61|5|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-62|5|884|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-63|5|888|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-64|5|890|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcutis over testis.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-65|5|891|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ midscapular.Skin Metastases  Muscle tsvs to muscle between r and l scapulae.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-66|5|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-67|5|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-68|5|904|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-69|5|904|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-70|5|905|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac metas to pt lns. Metastases  Muscle trac metast to sternal muscle.,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-71|5|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Skin tcvs to skin over testis.,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-72|5|911|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-73|5|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-74|5|925|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-75|5|933|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-76|5|940|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-77|5|946|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-78|5|946|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-79|5|954|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-80|5|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-81|5|963|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-82|5|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-83|5|968|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-84|5|968|Other deterministic changes|Whole body|MCDU/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-85|5|975|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-86|5|977|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-87|5|981|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-88|5|982|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-89|5|988|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-90|5|988|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis Head/neck missing, Eyes missing,MPATH: 212 - inflammation|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-91|5|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-92|5|997|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-93|5|1000|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ throat and lower jaw. Metastases  Muscle tcfs to muscle of throat and lower jaw.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-94|5|1010|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-95|5|1022|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS TO MUSCLE OF THROAT AND LOWER JAW.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-96|5|1023|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-97|5|1023|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-98|5|1035|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-99|5|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-100|5|1047|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-101|5|1047|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-102|5|1048|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-103|5|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-104|5|1059|Other deterministic changes|Whole body|MCDU/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-105|5|1065|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-106|5|1067|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-107|5|1069|Neoplasia unclassified|Other local manifestations and miscellaneus|TSWC: TCVS TO SKIN OVER TESTIS.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-108|5|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-109|5|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-110|5|1071|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ front limb. Metastases  Skin tbvs to skin fore limb. Metastases  Muscle tbvs to muscle fore limb.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-111|5|1072|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-112|5|1074|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-113|5|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-114|5|1075|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-115|5|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-116|5|1079|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-117|5|1080|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-118|5|1086|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO FACIAL MUSCLE.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-119|5|1090|Other deterministic changes|Whole body|MCDU/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-120|5|1094|Other deterministic changes|Whole body|MCDU/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-121|5|1096|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-122|5|1100|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-123|5|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-124|5|1101|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-125|5|1102|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-126|5|1107|Neoplasia malignant|Endocrine system|TGAC/ bilateral. Metastases Lung Metastases  Muscle tgac to facial muscle. Metastases  tgac to orbital sclera.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-127|5|1113|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-128|5|1117|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head/neck mis,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-129|5|1125|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-130|5|1127|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-131|5|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-132|5|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-133|5|1128|Other deterministic changes|Whole body|MCDU/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-134|5|1129|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-135|5|1130|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-136|5|1135|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-137|5|1137|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-138|5|1138|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-139|5|1142|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-140|5|1150|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-141|5|1158|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-142|5|1159|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-143|5|1159|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-144|5|1169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-145|5|1170|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ lower abdominal fat.|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-146|5|1177|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-147|5|1179|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-148|5|1179|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-149|5|1185|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-150|5|1191|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-151|5|1230|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-152|5|1263|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-153|5|1269|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-154|5|1293|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-155|5|1299|n/a|n/a|n/a|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-156|5|1305|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-157|5|1310|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-158|5|1345|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-159|5|1386|Other deterministic changes|Whole body|MCDU/|
1003-21-5|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 827± 16 lifespan study|1003-21-5-160|5|1398|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus.,MPATH: 218 - neoplasm|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-1|6|445|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-2|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-3|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-4|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-5|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-6|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-7|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-8|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-9|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-10|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-11|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-12|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-13|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-14|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-15|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-16|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-17|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-18|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-19|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-20|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-21|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-22|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-23|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-24|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-25|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-26|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-27|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-28|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-29|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-30|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-31|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-32|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-33|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-34|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-35|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-36|6|450|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-37|6|552|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-38|6|577|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-39|6|577|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-40|6|577|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-41|6|577|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-42|6|577|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-43|6|584|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-44|6|584|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-45|6|584|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-46|6|584|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-47|6|584|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-48|6|584|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-49|6|584|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-50|6|584|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-51|6|584|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-52|6|584|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-53|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-54|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-55|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-56|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-57|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-58|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-59|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-60|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-61|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-62|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-63|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-64|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-65|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-66|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-67|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-68|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-69|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-70|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-71|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-72|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-73|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-74|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-75|6|591|n/a|n/a|n/a|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-76|6|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-77|6|859|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ ventral side of animal; hind quarter. Metastases  Muscle tsec to muscle of thighs & abdomen.,MPATH: 218 - neoplasm|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-78|6|860|Other deterministic changes|Whole body|MCDU/|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-79|6|896|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWS: TSEC TO MUSCLE OF THIGHS & ABDOMEN.|
1003-21-6|n/a,S5|1|100|gamma-rays Co-60|1.43|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-6-80|6|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-1|7|112|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-2|7|251|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-3|7|296|Other deterministic changes|Whole body|MCDU/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-4|7|495|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-5|7|519|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-6|7|522|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-7|7|575|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle Metastases  tmvs to brown fat. Metastases Liver|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-8|7|590|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-9|7|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-10|7|628|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-11|7|640|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-12|7|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-13|7|661|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-14|7|673|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. LN.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-15|7|676|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-16|7|679|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-17|7|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  trac to visc. peritoneum.,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-18|7|687|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-19|7|687|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/ abdom. aorta.auricular|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-20|7|690|Other deterministic changes|Whole body|MCDU/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-21|7|698|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. LN..|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-22|7|724|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-23|7|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-24|7|738|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-25|7|738|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-26|7|742|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-27|7|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-28|7|753|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-29|7|753|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-30|7|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-31|7|758|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-32|7|760|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-33|7|764|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-34|7|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-35|7|768|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRVS/   Metastases  Lymphoret.System trvs to cervical ln..,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-36|7|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-37|7|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-38|7|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-39|7|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-40|7|786|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-41|7|786|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-42|7|787|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt. ln.,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-43|7|791|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-44|7|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-45|7|804|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-46|7|805|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO THOR. L.N..|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-47|7|806|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMVS OF THIGH TO LIVER.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-48|7|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-49|7|811|Other deterministic changes|Whole body|MCDU/  Head/neck missing, eyes missing|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-50|7|813|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-51|7|813|Other deterministic changes|Whole body|MCDU/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-52|7|814|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-53|7|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-54|7|820|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-55|7|830|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-56|7|831|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-57|7|838|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-58|7|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-59|7|864|Neoplasia malignant|Bloodvessels among cardiovascular system|TVVS/  Seminal vesicle|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-60|7|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Lymphoret.System trac to pt. ln..,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-61|7|867|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMVS OF THIGH TO LIVER.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-62|7|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-63|7|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-64|7|873|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ wall of colon.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-65|7|883|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-66|7|887|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-67|7|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-68|7|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-69|7|894|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-70|7|895|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-71|7|899|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-72|7|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-73|7|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-74|7|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-75|7|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-76|7|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-77|7|915|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-78|7|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-79|7|919|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. LN..|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-80|7|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Lymphoret.System trac to thor. l.n.. Metastases  Muscle trac to rib muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-81|7|921|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-82|7|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-83|7|929|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-84|7|931|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-85|7|935|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO PLEURA.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-86|7|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-87|7|939|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-88|7|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-89|7|942|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-90|7|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-91|7|948|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-92|7|950|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-93|7|953|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-94|7|953|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-95|7|963|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-96|7|969|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to gastric node. Metastases Heart Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-97|7|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-98|7|976|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMVS OF THIGH TO LIVER.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-99|7|980|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-100|7|981|Other deterministic changes|Whole body|MCDU/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-101|7|989|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-102|7|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-103|7|991|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh muscle. Muscle|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-104|7|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-105|7|994|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-106|7|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-107|7|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-108|7|1006|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-109|7|1009|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head neck missing, eyes missing,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-110|7|1015|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to muscle at base of skull.,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-111|7|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-112|7|1016|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-113|7|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-114|7|1027|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-115|7|1032|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRVS TO CERVICAL LN..|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-116|7|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-117|7|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-118|7|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-119|7|1051|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  Muscle trac to muscle of sternum.,MPATH: 242 - hemangiosarcoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-120|7|1051|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-121|7|1051|Other deterministic changes|Whole body|MCDU/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-122|7|1054|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcutis neck area.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-123|7|1058|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-124|7|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-125|7|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-126|7|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-127|7|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-128|7|1085|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-129|7|1088|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to rib cage muscles. Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-130|7|1092|Other deterministic changes|Whole body|MCDU/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-131|7|1093|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac to visc., parietal pleura.,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-132|7|1102|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to rib cage muscle. Metastases  Lymphoret.System trac to pt. ln.. Metastases  trac to pleura of rib cage.,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-133|7|1106|Neoplasia unclassified|Reproductive system|TTIO/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-134|7|1107|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-135|7|1114|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ jejunum.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-136|7|1116|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-137|7|1116|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-138|7|1144|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-139|7|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-140|7|1157|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-141|7|1159|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-142|7|1160|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma Metastases  trac to mediastinum.,MPATH: 218 - neoplasm|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-143|7|1164|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to mediastinum, pleural perit..,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-144|7|1171|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-145|7|1173|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-146|7|1178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-147|7|1180|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-148|7|1191|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-149|7|1198|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-150|7|1207|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-151|7|1221|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-152|7|1235|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-153|7|1235|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-154|7|1240|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-155|7|1240|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura.,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-156|7|1254|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-157|7|1254|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-158|7|1255|n/a|n/a|n/a|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-159|7|1277|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-7|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|160 (160 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|160 records survival 802± 16 lifespan study|1003-21-7-160|7|1346|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-1|8|333|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-2|8|347|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-3|8|354|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-4|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-5|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-6|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-7|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-8|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-9|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-10|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-11|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-12|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-13|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-14|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-15|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-16|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-17|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-18|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-19|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-20|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-21|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-22|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-23|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-24|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-25|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-26|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-27|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-28|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-29|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-30|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-31|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-32|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-33|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-34|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-35|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-36|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-37|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-38|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-39|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-40|8|450|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-41|8|480|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-42|8|486|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-43|8|577|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-44|8|577|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-45|8|577|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-46|8|577|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-47|8|577|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-48|8|577|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-49|8|577|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-50|8|577|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-51|8|577|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-52|8|577|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-53|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-54|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-55|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-56|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-57|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-58|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-59|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-60|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-61|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-62|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-63|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-64|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-65|8|584|Other deterministic changes|Whole body|MCDU/|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-66|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-67|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-68|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-69|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-70|8|584|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-71|8|591|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-72|8|591|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-73|8|591|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-74|8|591|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-75|8|591|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-76|8|591|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-77|8|591|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-78|8|591|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-79|8|591|n/a|n/a|n/a|
1003-21-8|n/a,S6|1|100|gamma-rays Co-60|2.06|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|6 records lifespan study females before or after 500 d after exposure|1003-21-8-80|8|591|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-1|9|332|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-2|9|364|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to intercostal muscle.,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-3|9|390|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac to pleura of rib cage.,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-4|9|452|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Muscle tgac to muscle around eye.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-5|9|453|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-6|9|463|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-7|9|547|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE AROUND EYE.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-8|9|565|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-9|9|575|Other deterministic changes|Whole body|MCDU/|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-10|9|591|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-11|9|606|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-12|9|607|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-13|9|612|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-14|9|612|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-15|9|614|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-16|9|617|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-17|9|624|Neoplasia unclassified|Other local manifestations and miscellaneus|THWS: TSVS OF NOSE TO LIVER.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-18|9|625|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-19|9|637|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS OF FACE INFILTRATING MUSCLE OF FACE & LYSING OF BONE.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-20|9|645|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-21|9|660|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  tiec of stomach to visc. peritoneum on spleen and kidney.,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-22|9|661|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-23|9|674|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-24|9|696|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-25|9|707|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-26|9|725|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-27|9|733|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-28|9|747|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-29|9|750|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-30|9|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-31|9|752|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-32|9|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-33|9|773|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWI: TIVS TRANSLUMINAL SPREAD TO VISCERAL PERITONEUM OF KID. PANC. AND TO MESENTERY. AND ABDOMINAL MUSCLE.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-34|9|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-35|9|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-36|9|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-37|9|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-38|9|785|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-39|9|787|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-40|9|787|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ rt. axillary region. Muscle|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-41|9|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-42|9|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-43|9|793|Other deterministic changes|Whole body|MCDU/|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-44|9|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-45|9|804|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ c.t. adj. to testis & epididymis.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-46|9|811|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ carc. stomach.,MPATH: 549 - carcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-47|9|817|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-48|9|818|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-49|9|823|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-50|9|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-51|9|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-52|9|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-53|9|840|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE AROUND EYE.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-54|9|841|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-55|9|842|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-56|9|849|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ abdominal muscles. Metastases  Lymphoret.System tmls to axillary lymph node.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-57|9|853|Neoplasia malignant|Endocrine system|TGAC/|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-58|9|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-59|9|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-60|9|869|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS TO MUSCLE OF MANDIBLE.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-61|9|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-62|9|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-63|9|884|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-64|9|884|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-65|9|886|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-66|9|892|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ left shoulder. Metastases Lung,MPATH: 219 - adnexal and skin appendage tumor|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-67|9|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-68|9|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-69|9|906|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-70|9|908|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-71|9|911|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-72|9|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-73|9|915|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-74|9|917|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-75|9|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-76|9|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-77|9|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-78|9|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-79|9|940|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ vertebral muscle.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-80|9|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-81|9|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-82|9|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  tmfs to spinal cord.,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-83|9|951|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE AROUND EYE.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-84|9|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-85|9|954|Neoplasia malignant|Endocrine system|TGAC/   Metastases  tgac to trigeminal nerve fiber. Metastases  Muscle tgac to muscle of skull.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-86|9|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-87|9|976|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-88|9|981|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCVS OF THE PELVIC REGION TO LUNG.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-89|9|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-90|9|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-91|9|997|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-92|9|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-93|9|1006|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ stomach. Metastases  tivs transluminal spread to visceral peritoneum of kid. panc. and to mesentery. and abdominal muscle.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-94|9|1006|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ face Metastases  Muscle tcfs of face infiltrating muscle of face & lysing of bone. Metastases  tcfs of face to nerve of face.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-95|9|1009|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-96|9|1016|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ nose.Skin Metastases Lung Metastases Heart Metastases  Muscle tsvs of nose to thoracic muscle.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-97|9|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-98|9|1026|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-99|9|1027|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ mandible. Metastases  Muscle tcfs to muscle of mandible.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-100|9|1030|Other deterministic changes|Whole body|MCDU/|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-101|9|1040|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-102|9|1044|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-103|9|1052|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVO/  ,MPATH: 240 - hemangioma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-104|9|1062|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ stomach. Metastases Liver,MPATH: 549 - carcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-105|9|1065|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-106|9|1066|Other deterministic changes|Whole body|MCDU/|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-107|9|1068|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-108|9|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-109|9|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-110|9|1087|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-111|9|1099|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ thigh.|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-112|9|1108|Other deterministic changes|Whole body|MCDU/|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-113|9|1143|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-114|9|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-115|9|1171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-116|9|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-117|9|1186|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-118|9|1200|n/a|n/a|n/a|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-119|9|1226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-9|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 744± 18 lifespan study|1003-21-9-120|9|1331|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-1|10|299|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-2|10|339|n/a|n/a|n/a|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-3|10|370|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-4|10|378|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-5|10|429|Other deterministic changes|Whole body|MCDU/|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-6|10|477|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-7|10|583|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-8|10|596|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ salivary gl.. Metastases  Lung txec of salivary gl. to lung.,MPATH: 446 - squamous cell carcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-9|10|612|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-10|10|631|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-11|10|653|n/a|n/a|n/a|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-12|10|666|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCFS OF PERIOSTEAL ARISING FROM SPINE TO LUNG.|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-13|10|681|n/a|n/a|n/a|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-14|10|688|Other deterministic changes|Whole body|MCDU/|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-15|10|711|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-16|10|759|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-17|10|762|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-18|10|767|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-19|10|775|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-20|10|778|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS TO SKELETAL MUSCLE ABOUT SPINE.|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-21|10|785|n/a|n/a|n/a|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-22|10|789|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-23|10|794|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MNIA/ brain.|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-24|10|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-25|10|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-26|10|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-27|10|807|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-28|10|815|n/a|n/a|n/a|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-29|10|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-30|10|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-31|10|829|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to rib cage muscle. Metastases  Lymphoret.System trac to pt. l.n..,MPATH: 268 - adenocarcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-32|10|834|n/a|n/a|n/a|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-33|10|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-34|10|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-35|10|848|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-36|10|851|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-37|10|858|n/a|n/a|n/a|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-38|10|876|n/a|n/a|n/a|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-39|10|893|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-40|10|896|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebrae.|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-41|10|896|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-42|10|901|Other deterministic changes|Whole body|MCDU/|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-43|10|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-44|10|950|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUAO/  Including papillary type,MPATH: 270 - adenoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-45|10|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-46|10|975|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ pelvis. Metastases  Muscle tcvs to skeletal muscle about spine.|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-47|10|976|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-48|10|979|Other deterministic changes|Whole body|MCDU/|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-49|10|1024|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ periosteal arising from spine. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-50|10|1026|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-51|10|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-52|10|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-53|10|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-54|10|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-55|10|1061|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-56|10|1066|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-57|10|1071|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-58|10|1125|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-59|10|1174|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-21-10|n/a,S7|1|100|gamma-rays Co-60|4.17|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|60 records survival 706± 27 lifespan study|1003-21-10-60|10|1233|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-1|11|211|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-2|11|253|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF RIB TO LUNG.|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-3|11|325|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-4|11|345|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWC: TCFS TO VISC. & PARIETAL PERIT..|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-5|11|346|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-6|11|346|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-7|11|356|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-8|11|386|Other deterministic changes|Whole body|MCDU/|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-9|11|402|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-10|11|405|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-11|11|407|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-12|11|412|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-13|11|428|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-14|11|435|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-15|11|441|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-16|11|446|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-17|11|462|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-18|11|463|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-19|11|471|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-20|11|477|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-21|11|487|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-22|11|516|Other deterministic changes|Whole body|MCDU/|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-23|11|519|Other deterministic changes|Whole body|MCDU/|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-24|11|543|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-25|11|565|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MPRA/  Prostatits|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-26|11|568|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ undetermined origin.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-27|11|572|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-28|11|575|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-29|11|582|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRVS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-30|11|585|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-31|11|598|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS OF NOSE TO MUSCLE IN REGION OF STOM..|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-32|11|604|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-33|11|625|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-34|11|631|Other deterministic changes|Whole body|MCDU/|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-35|11|635|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-36|11|635|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-37|11|638|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-38|11|639|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-39|11|646|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-40|11|655|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MUCA/  Cystitis|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-41|11|680|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-42|11|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-43|11|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-44|11|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-45|11|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-46|11|723|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-47|11|725|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ nose. Metastases  Muscle tcfs of nose to muscle in region of stom..,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-48|11|736|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-49|11|743|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-50|11|752|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-51|11|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-52|11|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-53|11|757|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-54|11|761|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-55|11|764|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-56|11|778|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ hind leg. Muscle|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-57|11|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-58|11|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-59|11|800|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWM: TMVS TO SPINAL CORD.|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-60|11|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-61|11|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-62|11|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-63|11|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-64|11|836|Other deterministic changes|Whole body|MCDU/  Head/neck missing, eyes missing|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-65|11|838|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis Metastases  tcfs to visc. & parietal perit..,MPATH: 212 - inflammation|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-66|11|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-67|11|842|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-68|11|843|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO RIB MUSCLES.|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-69|11|843|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ c.t. of chest. Metastases  Muscle tcfs of chest to rib cage (intercostal muscles).,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-70|11|852|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-71|11|858|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ muscle of thor. vert.. Muscle Metastases Lung tmvs to lung. Metastases  tmvs to spinal cord.|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-72|11|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-73|11|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-74|11|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-75|11|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-76|11|876|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWM: TMVS TO SPINAL CORD.|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-77|11|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-78|11|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Skin tcfs of chest to skin of thorax.,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-79|11|892|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-80|11|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-81|11|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-82|11|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-83|11|901|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-84|11|904|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-85|11|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-86|11|906|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-87|11|911|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-88|11|925|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-89|11|934|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-90|11|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-91|11|938|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-92|11|942|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-93|11|950|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh with invasion of skin. Muscle|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-94|11|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-95|11|952|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-96|11|960|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-97|11|961|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-98|11|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-99|11|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-100|11|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-101|11|971|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/  ,MPATH: 551 - sarcoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-102|11|976|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-103|11|978|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-104|11|981|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS OF CHEST TO RIB CAGE (INTERCOSTAL MUSCLES).|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-105|11|989|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ saliv. gl. mixed tumor with myoepitheliomatous component.,MPATH: 446 - squamous cell carcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-106|11|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-107|11|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-108|11|1029|n/a|n/a|n/a|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-109|11|1030|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Muscle tgac to rib muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-110|11|1030|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-111|11|1049|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ pancreas.|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-112|11|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-113|11|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-114|11|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-115|11|1069|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-116|11|1076|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-117|11|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-118|11|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-119|11|1101|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-11|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 646± 20 lifespan study|1003-21-11-120|11|1111|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-1|12|218|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-2|12|247|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS TO MUSCLE OF RIGHT HIND LEG.|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-3|12|250|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-4|12|274|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-5|12|277|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-6|12|310|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-7|12|328|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-8|12|331|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-9|12|341|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-10|12|353|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-11|12|365|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TBUS/ tooth tumor invading bone of maxilla.,MPATH: 551 - sarcoma|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-12|12|384|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-13|12|386|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-14|12|407|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-15|12|408|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-16|12|445|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-17|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-18|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-19|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-20|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-21|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-22|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-23|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-24|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-25|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-26|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-27|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-28|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-29|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-30|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-31|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-32|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-33|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-34|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-35|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-36|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-37|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-38|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-39|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-40|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-41|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-42|12|450|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-43|12|454|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-44|12|484|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-45|12|498|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-46|12|523|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-47|12|526|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-48|12|563|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-49|12|570|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-50|12|577|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-51|12|577|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-52|12|577|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-53|12|577|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-54|12|577|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-55|12|577|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-56|12|577|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-57|12|577|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-58|12|578|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-59|12|582|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-60|12|584|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-61|12|584|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-62|12|584|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-63|12|584|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-64|12|591|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-65|12|591|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-66|12|591|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-67|12|591|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-68|12|619|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-69|12|644|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-70|12|687|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-71|12|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-72|12|689|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-73|12|700|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver Metastases  Kidney tbos of femur to kidney. Metastases  Muscle to thigh muscle from tbos of femur.,MPATH: 268 - adenocarcinoma|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-74|12|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-75|12|710|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-76|12|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-77|12|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-78|12|737|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-79|12|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-80|12|773|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcut. right hind leg.|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-81|12|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-82|12|802|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Muscle tgac to skull.|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-83|12|805|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ left ear.,MPATH: 218 - neoplasm|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-84|12|813|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-85|12|815|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-86|12|820|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-87|12|831|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-88|12|835|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-89|12|842|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-90|12|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-91|12|848|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-92|12|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-93|12|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-94|12|863|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to mediastinum & visc. pleura of hrt. base. Metastases  Lymphoret.System trac to pt. l.n. & br. l.n.,MPATH: 268 - adenocarcinoma|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-95|12|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-96|12|872|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-97|12|899|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ right hind leg. Metastases  Muscle tcfs to muscle of right hind leg. Metastases  Skin tcfs to skin of right hind leg.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-98|12|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-99|12|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-100|12|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-101|12|910|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-102|12|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-103|12|919|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung Metastases Heart|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-104|12|933|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-105|12|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-106|12|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-107|12|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-108|12|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-109|12|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-110|12|962|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-111|12|974|Other deterministic changes|Whole body|MCDU/|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-112|12|978|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Muscle tgac to adnexa of eye.|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-113|12|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-114|12|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-115|12|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-116|12|1013|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-117|12|1016|n/a|n/a|n/a|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-118|12|1022|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-119|12|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-12|n/a,S8|1|100|gamma-rays Co-60|5.69|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|78 records survival 645± 25 lifespan study|1003-21-12-120|12|1138|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-1|13|397|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-2|13|418|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ in cheek - rt. jaw.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-3|13|454|Neoplasia unclassified|Central nervous system among nervous system|TNXS/ cerebellum.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-4|13|475|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-5|13|484|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-6|13|489|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-7|13|499|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-8|13|515|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-9|13|534|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-10|13|537|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-11|13|553|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-12|13|568|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-13|13|568|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-14|13|578|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-15|13|630|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-16|13|638|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-17|13|647|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-18|13|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-19|13|649|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWA: TACC TO LUNG.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-20|13|656|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-21|13|661|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-22|13|662|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-23|13|666|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-24|13|668|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-25|13|676|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-26|13|681|Neoplasia malignant|Endocrine system|TGAC/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-27|13|687|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-28|13|698|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-29|13|704|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to diaphragm. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-30|13|708|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-31|13|708|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-32|13|716|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-33|13|718|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-34|13|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-35|13|720|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-36|13|726|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ calvarium. Metastases  tcvs to brain.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-37|13|726|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-38|13|732|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/  ,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-39|13|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-40|13|738|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO RIB CAGE.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-41|13|742|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-42|13|748|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/  Head/neck missing, eyes missing, thorax missing,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-43|13|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-44|13|756|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG & PARIETAL PLEURA OF RIB CAGE.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-45|13|759|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma Metastases  tpac to base of cerebrum.,MPATH: 218 - neoplasm|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-46|13|760|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-47|13|761|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-48|13|761|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-49|13|761|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute, Head/neck missing,MPATH: 212 - inflammation|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-50|13|763|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE OF FACE.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-51|13|766|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-52|13|767|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-53|13|771|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-54|13|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-55|13|774|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac to skel. muscle of head.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-56|13|774|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-57|13|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-58|13|778|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  trac to pleural tissue. Metastases  Muscle trac to skeletal muscles of thorax.,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-59|13|779|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-60|13|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-61|13|789|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-62|13|792|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-63|13|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-64|13|799|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ small intestine.Enteritis acute,MPATH: 212 - inflammation|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-65|13|800|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-66|13|803|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-67|13|806|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-68|13|808|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-69|13|809|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-70|13|810|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-71|13|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-72|13|819|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-73|13|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-74|13|823|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-75|13|824|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-76|13|827|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-77|13|828|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-78|13|830|Neoplasia unclassified|Kidney among urinary system diseases,MA: 0000368 - kidney|TKTC/  Transitional cells,MPATH: 218 - neoplasm|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-79|13|830|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Liver Metastases  Muscle tkac to diaphragm. Metastases  Lymphoret.System tkac to renal l.n. Metastases Lung Metastases  tkac to pancreas.,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-80|13|830|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-81|13|832|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-82|13|833|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-83|13|834|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-84|13|836|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-85|13|844|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-86|13|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-87|13|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-88|13|855|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/   Metastases Heart,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-89|13|856|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWC: TCVS TO BRAIN.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-90|13|858|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-91|13|858|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO P.T. L.N..|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-92|13|867|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-93|13|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-94|13|875|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE OF FACE.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-95|13|877|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-96|13|879|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ salivary gland. Metastases  txac of the salivary gland to jaw.,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-97|13|880|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-98|13|880|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-99|13|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-100|13|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-101|13|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-102|13|890|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-103|13|901|Inflammation and/or fibrotic diseases|Integumentary system|MSDA/  acute|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-104|13|901|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-105|13|904|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-106|13|908|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO BRACHIAL & AXILLARY NODES.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-107|13|908|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-108|13|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-109|13|909|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-110|13|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-111|13|913|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-112|13|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-113|13|916|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-114|13|922|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-115|13|928|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-116|13|936|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-117|13|937|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ salivary gland.,MPATH: 446 - squamous cell carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-118|13|939|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-119|13|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-120|13|941|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-121|13|947|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWP: TPAC TO BASE OF CEREBRUM.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-122|13|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-123|13|950|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney Metastases  Muscle trac to sternal muscle.,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-124|13|951|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-125|13|953|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to rib cage. Metastases  trac to visc. pleura.,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-126|13|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-127|13|955|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-128|13|955|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases Lung,MPATH: 242 - hemangiosarcoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-129|13|959|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-130|13|959|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-131|13|964|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-132|13|964|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-133|13|967|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-134|13|968|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac to muscle of face.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-135|13|968|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-136|13|970|Neoplasia malignant|Endocrine system|TGAC/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-137|13|972|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ ileum.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-138|13|974|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-139|13|975|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE OF FACE.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-140|13|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-141|13|975|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-142|13|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-143|13|979|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-144|13|981|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-145|13|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-146|13|983|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-147|13|983|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-148|13|988|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWA: TACC TO LUNG.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-149|13|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-150|13|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  txec of salivary gland to muscle of jaw and tongue.,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-151|13|991|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-152|13|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-153|13|995|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-154|13|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-155|13|998|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-156|13|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-157|13|999|Neoplasia malignant|Endocrine system|TGAC/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-158|13|1009|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-159|13|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-160|13|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-161|13|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-162|13|1012|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-163|13|1015|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to sternal muscle.,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-164|13|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-165|13|1019|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-166|13|1022|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-167|13|1023|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO DIAPHRAGM.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-168|13|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-169|13|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  Lymphoret.System trac to brachial & axillary nodes.,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-170|13|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-171|13|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-172|13|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-173|13|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-174|13|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to sternal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-175|13|1045|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-176|13|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-177|13|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-178|13|1053|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-179|13|1053|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-180|13|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-181|13|1059|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-182|13|1059|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-183|13|1061|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-184|13|1064|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to muscle of rib cage. Metastases  Lymphoret.System trac to p.t. l.n..,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-185|13|1064|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-186|13|1065|Neoplasia unclassified|Other local manifestations and miscellaneus|THWK: TKAC TO LIVER.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-187|13|1066|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-188|13|1076|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000099 - pericardium|MPCA/  acute,MPATH: 212 - inflammation|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-189|13|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-190|13|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-191|13|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-192|13|1084|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-193|13|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-194|13|1098|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-195|13|1101|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXUO/ sal. gl. myoepithelioma.,MPATH: 218 - neoplasm|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-196|13|1108|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System tktc to renal l.n.,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-197|13|1110|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-198|13|1114|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-199|13|1123|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-200|13|1126|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-201|13|1128|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-202|13|1129|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-203|13|1129|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-204|13|1131|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-205|13|1136|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-206|13|1142|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-207|13|1152|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-208|13|1153|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  tkac to visceral peritoneum.,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-209|13|1156|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-210|13|1157|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to visc. and parietal pleura. Metastases  Muscle trac to rib cage. Metastases  Lymphoret.System trac to p.t. l.n..,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-211|13|1158|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-212|13|1162|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-213|13|1165|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-214|13|1171|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-215|13|1171|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-216|13|1172|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum.Enteritis acute,MPATH: 212 - inflammation|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-217|13|1172|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Muscle tgac to muscle of face.,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-218|13|1175|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO BRACHIAL & AXILLARY NODES.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-219|13|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-220|13|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-221|13|1191|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-222|13|1200|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-223|13|1206|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-224|13|1207|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-225|13|1212|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-226|13|1215|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-227|13|1219|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-228|13|1222|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-229|13|1226|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-230|13|1226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-231|13|1229|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-232|13|1232|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-233|13|1240|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-234|13|1243|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-235|13|1244|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-236|13|1248|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-237|13|1250|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-238|13|1251|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-239|13|1256|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-240|13|1258|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-241|13|1270|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-242|13|1275|n/a|n/a|n/a|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-243|13|1283|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-244|13|1289|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-245|13|1307|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-246|13|1318|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-247|13|1341|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-248|13|1345|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-249|13|1394|Other deterministic changes|Whole body|MCDU/|
1003-21-13|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|249 records survival 826± 13 lifespan study|1003-21-13-250|13|1412|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-1|14|194|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-2|14|249|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-3|14|281|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-4|14|282|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-5|14|298|Neoplasia unclassified|Other local manifestations and miscellaneus|TIWU: TUVS TO COLON AND MUSCLE OF ABD. WALL.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-6|14|299|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal,MPATH: 218 - neoplasm|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-7|14|375|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-8|14|400|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/   Metastases  GI tract tuvs to colon and muscle of abd. wall.,MPATH: 242 - hemangiosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-9|14|411|Neoplasia malignant|Endocrine system|TGAC/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-10|14|471|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-11|14|488|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-12|14|500|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-13|14|512|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-14|14|514|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-15|14|524|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-16|14|546|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-17|14|548|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF LUMBAR VERT. TO MUSCLES IN LUMBAR REGION.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-18|14|551|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-19|14|562|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ face - over nose & eyes.Skin|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-20|14|563|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-21|14|603|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMTA/  Metritis|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-22|14|610|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-23|14|613|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-24|14|624|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-25|14|628|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-26|14|630|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-27|14|638|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS TO MUSCLE OF LUMBAR SACRAL REGION.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-28|14|640|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-29|14|650|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-30|14|653|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-31|14|656|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-32|14|658|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-33|14|658|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-34|14|662|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-35|14|670|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-36|14|674|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-37|14|682|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-38|14|683|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-39|14|694|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS TO MUSCLE OF THORACIC AREA.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-40|14|698|Neoplasia malignant|Endocrine system|TGAC/   Metastases Liver Metastases  Muscle tgac to muscles of calvarium surface.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-41|14|698|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-42|14|701|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-43|14|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-44|14|704|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-45|14|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-46|14|710|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-47|14|711|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-48|14|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-49|14|712|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-50|14|716|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-51|14|717|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-52|14|722|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-53|14|746|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-54|14|747|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-55|14|753|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-56|14|771|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung Metastases  Lymphoret.System thac to mn. l.n.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-57|14|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-58|14|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-59|14|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-60|14|784|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar spine. Metastases Lung|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-61|14|787|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-62|14|788|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-63|14|788|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  tcfs to parietal peritoneum.,MPATH: 242 - hemangiosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-64|14|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-65|14|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-66|14|789|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-67|14|789|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-68|14|790|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-69|14|790|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-70|14|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-71|14|795|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-72|14|799|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ pelvic region with lysis of bone and invasion of colon. Metastases  Skin tcfs to skin of pelvic region.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-73|14|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-74|14|803|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-75|14|803|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-76|14|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-77|14|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-78|14|814|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ vaginal wall.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-79|14|815|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-80|14|815|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-81|14|816|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-82|14|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-83|14|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-84|14|825|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-85|14|827|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-86|14|836|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ skin of left axilla.Skin Metastases  Muscle tsvs to skeletal muscle of forelimb.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-87|14|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-88|14|840|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ inguinal region. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-89|14|841|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-90|14|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-91|14|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-92|14|851|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-93|14|856|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|TZAC/  ,MPATH: 278 - follicular adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-94|14|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-95|14|859|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-96|14|860|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-97|14|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-98|14|862|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF LUMBAR SPINE TO LUNG.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-99|14|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-100|14|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-101|14|867|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-102|14|869|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-103|14|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-104|14|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-105|14|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-106|14|871|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-107|14|873|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-108|14|876|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-109|14|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-110|14|877|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vert.. Metastases  Muscle tbos of lumbar vert. to muscles in lumbar region.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-111|14|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-112|14|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-113|14|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-114|14|880|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  trac to pleura. Metastases  Lymphoret.System trac to p.t. l.n..,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-115|14|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-116|14|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-117|14|887|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-118|14|890|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases Lung|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-119|14|893|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-120|14|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-121|14|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-122|14|897|Neoplasia unclassified|Other local manifestations and miscellaneus|TKAC: TKAC TO LUNG.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-123|14|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  tuac invasion of ur. bl. and ureter. Metastases  GI tract tuac to colon.,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-124|14|903|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ thoracic spine.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-125|14|904|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-126|14|904|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-127|14|905|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ inguinal region.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-128|14|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-129|14|907|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-130|14|911|Neoplasia unclassified|Other local manifestations and miscellaneus|THWG: TGAC TO LIVER.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-131|14|911|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-132|14|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-133|14|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-134|14|918|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-135|14|918|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MPNE/  acute,MPATH: 212 - inflammation|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-136|14|921|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-137|14|921|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-138|14|921|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-139|14|925|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-140|14|927|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-141|14|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-142|14|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-143|14|929|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-144|14|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-145|14|934|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-146|14|935|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO PARIETAL PLEURA.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-147|14|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-148|14|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-149|14|941|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-150|14|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-151|14|941|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-152|14|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-153|14|946|Neoplasia unclassified|Other local manifestations and miscellaneus|TIWU: TUVS TO COLON AND MUSCLE OF ABD. WALL.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-154|14|948|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWZ: TZAC TO LUNG.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-155|14|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-156|14|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-157|14|953|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-158|14|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-159|14|954|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-160|14|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-161|14|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-162|14|960|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF FEMUR TO THIGH MUSCLE.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-163|14|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-164|14|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-165|14|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-166|14|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-167|14|964|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tcfs to muscle of thoracic area.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-168|14|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-169|14|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-170|14|977|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebrae. Metastases  Muscle tbos to skeletal muscle adjac. to vert.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-171|14|979|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-172|14|981|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-173|14|985|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ beneath brain.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-174|14|988|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-175|14|990|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tcfs to muscle of lumbar region.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-176|14|992|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-177|14|995|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-178|14|996|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ intercostal muscle.muscle Metastases  Lymphoret.System tmfs to pt. and br. l.n.'s. Metastases Lung tmfs to lung. Metastases  tmsf to visceral & parietal pleura.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-179|14|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-180|14|997|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-181|14|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-182|14|999|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus.,MPATH: 218 - neoplasm|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-183|14|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-184|14|1005|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar--sacral vert.. Metastases  Lung mult. metas. similar to hard. gl. ad. ca. with vac. cytopl.; no primary found.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-185|14|1008|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ thorax. Metastases  tcfs to parietal & visceral peritoneum. Metastases  Muscle tcfs to intercostal muscle.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-186|14|1009|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWO: TOGC TO LUNG.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-187|14|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-188|14|1018|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-189|14|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-190|14|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-191|14|1036|n/a|n/a|n/a|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-192|14|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-193|14|1047|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-194|14|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-195|14|1052|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-196|14|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-197|14|1054|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-198|14|1055|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-199|14|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-200|14|1058|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-201|14|1061|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-202|14|1062|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-203|14|1065|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-204|14|1067|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-205|14|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-206|14|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-207|14|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Skin tcfs to skin of abdomen.,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-208|14|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-209|14|1082|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ fallopian tube with visceral-peritoneal spread.,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-210|14|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-211|14|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-212|14|1089|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to parietal pleura.,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-213|14|1093|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-214|14|1096|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-215|14|1096|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-216|14|1102|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-217|14|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-218|14|1109|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-219|14|1111|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-220|14|1121|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-221|14|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-222|14|1123|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases Lung Metastases  Muscle tbos of femur to thigh muscle.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-223|14|1129|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-224|14|1133|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ skull. Metastases  tbos of skull to brain. Metastases  Skin tbos of skull to skin of the nose.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-225|14|1134|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-226|14|1136|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-227|14|1139|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-228|14|1146|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-229|14|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-230|14|1150|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-231|14|1153|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-232|14|1155|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-233|14|1156|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-234|14|1164|Other deterministic changes|Whole body|MCDU/|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-235|14|1164|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ area of lumbar sacral spine. Metastases  Muscle tcvs to muscle of lumbar sacral region.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-236|14|1166|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWB: TBOS OF SKULL TO BRAIN.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-237|14|1167|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-238|14|1169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-239|14|1173|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-240|14|1174|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-241|14|1178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-242|14|1185|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ scapula. Metastases  Muscle tcfs to muscles of rib cage and mid-back.|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-243|14|1195|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-244|14|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-245|14|1213|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-246|14|1226|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/  ,MPATH: 218 - neoplasm|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-247|14|1233|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-248|14|1247|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-249|14|1254|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-14|n/a,S4|1|100|neutrons fission|0.2|grays|External exposure|code S4 1 fraction 20 m|250 (250 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|244 records survival 778± 13 lifespan study|1003-21-14-250|14|1338|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney Metastases  Lymphoret.System trac to renal & axillary l.n. Metastases  Muscle trac to skeletal muscle head & brachial plexus. Metastases  trac to visceral pleura & visc. perit. & aorta. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-1|15|295|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWC: TCFS OF LEFT SHOULDER TO PT. L.N.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-2|15|361|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-3|15|456|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-4|15|464|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-5|15|473|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-6|15|477|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-7|15|559|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to chest muscles. Metastases  trac to parietal pleura, mediastinum,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-8|15|568|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-9|15|568|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO PT. L.N.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-10|15|575|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-11|15|577|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-12|15|587|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ left shoulder region. Metastases Lung Metastases  Lymphoret.System tcfs of left shoulder to pt. l.n. Metastases  Muscle tcfs of left shoulder to rib cage muscle. Metastases Heart tcfs of left shoulder to heart.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-13|15|593|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-14|15|598|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ inguinal region.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-15|15|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-16|15|606|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ salivary gland.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-17|15|611|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-18|15|611|Other deterministic changes|Whole body|MCDU/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-19|15|621|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-20|15|629|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-21|15|632|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-22|15|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-23|15|645|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ left axillary region. Metastases  Muscle tcvs to axillary muscles.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-24|15|657|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lymphoret.System tgac to pt. l.n. Metastases  Muscle tgac to diaphragm & intercostal muscles.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-25|15|666|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-26|15|667|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-27|15|668|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileum.,MPATH: 218 - neoplasm|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-28|15|677|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-29|15|687|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-30|15|688|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-31|15|689|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-32|15|695|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-33|15|704|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-34|15|718|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenum.,MPATH: 218 - neoplasm|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-35|15|720|Other deterministic changes|Whole body|MCDU/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-36|15|726|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-37|15|730|Other deterministic changes|Whole body|MCDU/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-38|15|736|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-39|15|736|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-40|15|737|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-41|15|738|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-42|15|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-43|15|745|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-44|15|746|Other deterministic changes|Whole body|MCDU/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-45|15|754|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWC: TCFS OF LEFT SHOULDER TO PT. L.N.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-46|15|756|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF FEMUR TO MUSCLE OF FEMUR.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-47|15|763|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ORBITAL ADNEXAL MUSCLE.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-48|15|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-49|15|768|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-50|15|768|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS TO AXILLARY MUSCLES.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-51|15|771|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-52|15|773|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS TO AXIL. REG.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-53|15|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-54|15|778|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-55|15|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases Seminal vesicle,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-56|15|785|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF LUMBAR VERT. TO VERT. MUSCLE.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-57|15|789|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-58|15|792|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System tiac of jejunum to mn. l.n. Metastases  Lymphoret.System tkac to rn. l.n. Metastases  Lymphoret.System trac to thoracic nodes,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-59|15|793|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-60|15|808|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ rt. axil.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-61|15|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-62|15|810|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-63|15|812|Neoplasia malignant|Bloodvessels among cardiovascular system|TLVS/ mn. ln.. Lymphoret.tissue Metastases Heart|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-64|15|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-65|15|824|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-66|15|824|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-67|15|826|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-68|15|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-69|15|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-70|15|834|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-71|15|836|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ salivary gland.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-72|15|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-73|15|842|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-74|15|848|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-75|15|849|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-76|15|851|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-77|15|856|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-78|15|856|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-79|15|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-80|15|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-81|15|864|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver Metastases  Lymphoret.System trac to pt. l.n.,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-82|15|865|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-83|15|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-84|15|873|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-85|15|874|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ORBITAL ADNEXAL MUSCLE.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-86|15|877|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-87|15|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-88|15|880|Inflammation and/or fibrotic diseases|Heart among cardiovascular system,MA: 0000076 - heart endocardium|MECC/  Chronic valvular endocarditis Metastases Lung,MPATH: 214 - chronic inflammation|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-89|15|884|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-90|15|884|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/   Metastases  Muscle tbos of femur to muscle of femur.,MPATH: 242 - hemangiosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-91|15|885|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-92|15|885|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS TO AXIL. REG.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-93|15|887|Neoplasia malignant|Endocrine system|TGAC/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-94|15|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-95|15|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-96|15|903|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-97|15|907|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-98|15|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-99|15|911|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases  tkac to visc. perit.,MPATH: 549 - carcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-100|15|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-101|15|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-102|15|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-103|15|924|Other deterministic changes|Whole body|MCDU/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-104|15|930|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-105|15|932|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-106|15|932|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-107|15|934|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-108|15|934|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWI: TIAC OF PYLORUS TO KIDNEY.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-109|15|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-110|15|939|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-111|15|942|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-112|15|943|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-113|15|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-114|15|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-115|15|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-116|15|955|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ADNEXAL ORBITAL MUSCLE.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-117|15|955|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-118|15|955|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNUS/ brain.,MPATH: 551 - sarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-119|15|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-120|15|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-121|15|962|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Skin tcfs to skin over tumor mass left shoulder.,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-122|15|963|Neoplasia unclassified|Endocrine system,MA: 0001247 - harderian gland|TGSC/  undifferentiated tumor Metastases  Lymphoret.System tgsc to c.n. l.n.. Metastases Lung,MPATH: 218 - neoplasm|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-123|15|967|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-124|15|968|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases  Muscle tgac to orbital adnexal muscle. Metastases  tgac to orbital tissue.,MPATH: 549 - carcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-125|15|969|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-126|15|971|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-127|15|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-128|15|975|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-129|15|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-130|15|984|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ rt. hip.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-131|15|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-132|15|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-133|15|995|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-134|15|1003|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-135|15|1005|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-136|15|1007|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-137|15|1009|Other deterministic changes|Whole body|MCDU/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-138|15|1009|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-139|15|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-140|15|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-141|15|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-142|15|1030|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Muscle tgac to muscle & skin of skull.,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-143|15|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-144|15|1034|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-145|15|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-146|15|1037|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK. TKAC TO LUNG.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-147|15|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-148|15|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tgac to adnexal orbital muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-149|15|1051|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-150|15|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-151|15|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-152|15|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung Metastases  tgac to visc. and parietal pleura.,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-153|15|1066|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-154|15|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-155|15|1075|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-156|15|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-157|15|1091|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-158|15|1096|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-159|15|1097|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus. Metastases  Lymphoret.System tiac of pylorus to cn l.n.. Metastases  tiac of pylorus to pancreas. Metastases  Kidney tiac of pylorus to kidney.,MPATH: 218 - neoplasm|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-160|15|1100|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-161|15|1101|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-162|15|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-163|15|1107|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-164|15|1107|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-165|15|1110|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-166|15|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-167|15|1122|Other deterministic changes|Whole body|MCDU/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-168|15|1124|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-169|15|1128|Neoplasia malignant|Bloodvessels among cardiovascular system|TDVS/  Urinary bladder|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-170|15|1129|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-171|15|1131|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vert. Metastases  tbos of lumbar vert. to spinal cord & nerve fibers. Metastases  Muscle tbos of lumbar vert. to vert. muscle.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-172|15|1141|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Muscle tcvs to axil. reg.,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-173|15|1146|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-174|15|1149|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-175|15|1156|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-176|15|1158|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-177|15|1160|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-178|15|1163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-179|15|1169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-180|15|1170|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-181|15|1174|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-182|15|1177|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-183|15|1181|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-184|15|1191|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-185|15|1195|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-186|15|1200|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-187|15|1204|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-188|15|1205|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-189|15|1206|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. L.N.|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-190|15|1214|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-191|15|1219|Other deterministic changes|Whole body|MCDU/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-192|15|1223|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-193|15|1227|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lymphoret.System trac to pt. l.n.,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-194|15|1229|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-195|15|1263|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-196|15|1299|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-197|15|1309|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-198|15|1312|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-199|15|1352|n/a|n/a|n/a|
1003-21-15|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|199 records survival 798± 14 lifespan study|1003-21-15-200|15|1359|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-1|16|374|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-2|16|403|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh, back & abd. wall. Muscle|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-3|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-4|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-5|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-6|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-7|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-8|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-9|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-10|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-11|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-12|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-13|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-14|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-15|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-16|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-17|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-18|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-19|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-20|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-21|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-22|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-23|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-24|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-25|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-26|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-27|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-28|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-29|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-30|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-31|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-32|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-33|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-34|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-35|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-36|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-37|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-38|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-39|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-40|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-41|16|450|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-42|16|489|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-43|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-44|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-45|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-46|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-47|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-48|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-49|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-50|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-51|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-52|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-53|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-54|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-55|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-56|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-57|16|577|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-58|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-59|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-60|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-61|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-62|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-63|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-64|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-65|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-66|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-67|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-68|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-69|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-70|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-71|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-72|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-73|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-74|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-75|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-76|16|591|n/a|n/a|n/a|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-77|16|771|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWK: TKAC TO HEART.|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-78|16|863|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-79|16|912|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Heart,MPATH: 549 - carcinoma|
1003-21-16|n/a,S5|1|100|neutrons fission|0.4|grays|External exposure|code S5 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-16-80|16|1001|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-1|17|352|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-2|17|394|Other deterministic changes|Whole body|MCDU/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-3|17|397|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE OF HEAD.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-4|17|404|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ cowpers gland.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-5|17|420|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE OF HEAD.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-6|17|450|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-7|17|456|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-8|17|470|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-9|17|529|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-10|17|535|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-11|17|556|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO PLEURA OF THORAX.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-12|17|568|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-13|17|595|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-14|17|596|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-15|17|598|Other deterministic changes|Whole body|MCDU/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-16|17|600|Other deterministic changes|Whole body|MCDU/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-17|17|603|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-18|17|606|Inflammation and/or fibrotic diseases|Integumentary system|MSDA/  acute|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-19|17|609|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-20|17|610|Other deterministic changes|Whole body|MCDU/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-21|17|616|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-22|17|625|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-23|17|625|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-24|17|631|Neoplasia unclassified|Other local manifestations and miscellaneus|THWC: TCVS TO LIVER.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-25|17|632|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE OF RIBS & ORBIT.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-26|17|634|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ scrotum and adnexa in pelvic region.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-27|17|649|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-28|17|667|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis, Eyes missing|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-29|17|670|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ thor. spine.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-30|17|673|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-31|17|674|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKVS/  ,MPATH: 551 - sarcoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-32|17|680|Neoplasia malignant|Other local manifestations and miscellaneus|TMSS/ TMSS/ TMSS/ TMSS/ muscle of mandible.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-33|17|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-34|17|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-35|17|695|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-36|17|696|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvis. Metastases  GI tract tbos of pelivs to gut & ur. bl. wall. Metastases  Muscle tbos to muscle of pelvis.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-37|17|698|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-38|17|702|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-39|17|709|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-40|17|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-41|17|718|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-42|17|724|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-43|17|725|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-44|17|728|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-45|17|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-46|17|743|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO CHEEK MUSCLE.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-47|17|748|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-48|17|761|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ tail base. Metastases  Muscle tcfs to muscle & rectal wall. Metastases  Skin tcfs to skin at tail base.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-49|17|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-50|17|766|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-51|17|766|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-52|17|768|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-53|17|772|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO MEDIASTINUM.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-54|17|784|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-55|17|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-56|17|786|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-57|17|789|Neoplasia systemic|Haematolymphatic system|TLML/   Metastases  Muscle rib cage muscle by tcfs.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-58|17|790|Neoplasia malignant|Endocrine system|TGAC/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-59|17|796|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBVS OF LUMBAR SPINE TO MUSCLE OF SPINE.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-60|17|798|Other deterministic changes|Whole body|MCDU/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-61|17|807|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWZ: TZAC THYROID MILIARY METASTASIS TO LUNG.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-62|17|821|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWX: TXAC TO SKELETAL MUSCLE IN NECK REGION.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-63|17|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-64|17|823|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-65|17|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-66|17|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-67|17|835|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-68|17|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-69|17|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-70|17|842|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-71|17|846|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-72|17|850|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-73|17|850|Neoplasia unclassified|Other local manifestations and miscellaneus|TIWB: TBOS OF PELIVS TO GUT & UR. BL. WALL.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-74|17|853|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-75|17|855|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-76|17|856|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Liver Metastases Lung Metastases  tkac to visceral peritoneum. Metastases  Lymphoret.System tkac to rn. ln..,MPATH: 549 - carcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-77|17|857|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac to orbital muscles. Metastases Lung|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-78|17|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Lung txac in lung.,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-79|17|860|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to cn. ln.. Metastases  tgac to visc. parietal pleura. Metastases Lung|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-80|17|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-81|17|869|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBVS OF LUMBAR SPINE TO MUSCLE OF SPINE.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-82|17|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-83|17|878|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-84|17|878|Other deterministic changes|Whole body|MCDU/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-85|17|879|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ bilateral.,MPATH: 549 - carcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-86|17|880|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-87|17|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-88|17|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-89|17|883|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head meck missing,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-90|17|887|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: RIB CAGE MUSCLE BY TCFS.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-91|17|890|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ lumbar spine. Metastases  Muscle tbvs of lumbar spine to muscle of spine.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-92|17|891|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-93|17|893|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-94|17|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-95|17|898|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ duodenum.Enteritis acute,MPATH: 212 - inflammation|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-96|17|899|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-97|17|899|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-98|17|910|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-99|17|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-100|17|913|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-101|17|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-102|17|918|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-103|17|918|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-104|17|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-105|17|921|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-106|17|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-107|17|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-108|17|924|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: RIB CAGE MUSCLE BY TCFS.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-109|17|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-110|17|928|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura of thorax.,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-111|17|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-112|17|932|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-113|17|932|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-114|17|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-115|17|941|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-116|17|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-117|17|947|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ thor. vert. Metastases  Muscle tbvs to thor. vert. - muscle.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-118|17|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-119|17|953|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ORBITAL MUSCLES.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-120|17|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-121|17|961|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-122|17|963|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-123|17|967|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-124|17|967|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS TO MUSCLE & RECTAL WALL.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-125|17|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-126|17|974|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-127|17|976|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-128|17|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-129|17|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-130|17|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-131|17|981|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Muscle tgac to muscle of ribs & orbit.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-132|17|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-133|17|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-134|17|987|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung Metastases Lung|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-135|17|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-136|17|990|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ salivary gland & skin adj. to ear. Metastases Lung Metastases  Skin tcvs to skin of neck & ear from sal. gl. Metastases Liver Metastases  tcvs to salivary gl.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-137|17|995|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-138|17|997|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-139|17|999|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,  HHead/neck missing, eyes missing,MPATH: 218 - neoplasm|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-140|17|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-141|17|1003|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-142|17|1003|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-143|17|1005|Neoplasia unclassified|Central nervous system among nervous system|TNAS/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-144|17|1009|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-145|17|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-146|17|1013|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-147|17|1014|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-148|17|1016|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-149|17|1017|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ no norm. organ present; in region of salivary gland. Metastases  txac to skeletal muscle in neck region. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-150|17|1019|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-151|17|1023|Other deterministic changes|Whole body|MCDU/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-152|17|1030|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-153|17|1033|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-154|17|1033|Neoplasia malignant|Endocrine system|TGAC/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-155|17|1039|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|TZAC/ thyroid. Metastases Lung,MPATH: 278 - follicular adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-156|17|1041|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-157|17|1045|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to mediastinum.,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-158|17|1045|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-159|17|1051|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-160|17|1058|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-161|17|1060|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-162|17|1062|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-163|17|1065|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-164|17|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-165|17|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-166|17|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-167|17|1072|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-168|17|1072|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-169|17|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-170|17|1074|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-171|17|1076|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tgac to cheek muscle.,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-172|17|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-173|17|1083|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus.,MPATH: 218 - neoplasm|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-174|17|1088|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ sem. ves. & epididymis.,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-175|17|1089|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Muscle tgac to rib muscles.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-176|17|1090|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-177|17|1096|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXUO/ adenocarc. infiltr. fat.  primary origin unknown. metastasis to mediastinum.,MPATH: 218 - neoplasm|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-178|17|1107|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac to muscle of skull. Metastases Lung|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-179|17|1115|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Heart Metastases Lung Metastases  tkac to visceral perit.,MPATH: 549 - carcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-180|17|1120|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-181|17|1123|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-182|17|1131|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  Muscle tgac to muscle of head.,MPATH: 242 - hemangiosarcoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-183|17|1135|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tgac to muscle of orbit.,MPATH: 268 - adenocarcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-184|17|1146|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-185|17|1186|n/a|n/a|n/a|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-186|17|1188|Other deterministic changes|Whole body|MCDU/|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-187|17|1195|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-188|17|1197|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-189|17|1214|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-190|17|1223|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-191|17|1230|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-192|17|1240|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-193|17|1256|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ ileum.|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-194|17|1262|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-195|17|1268|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCA/ MMCA/ MMCA/ MMCA/  acute,MPATH: 212 - inflammation|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-196|17|1271|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ rib cage.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-197|17|1285|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-198|17|1288|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCA/ MMCA/ MMCA/ MMCA/  acute,MPATH: 212 - inflammation|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-199|17|1303|Other deterministic changes|Hepato-pancreatic system|MHCY/  Hepatic cyst|
1003-21-17|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 780± 14 lifespan study|1003-21-17-200|17|1338|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-1|18|156|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-2|18|358|Other deterministic changes|Whole body|MCDU/|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-3|18|387|Other deterministic changes|Whole body|MCDU/|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-4|18|411|Other deterministic changes|Whole body|MCDU/|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-5|18|444|Other deterministic changes|Whole body|MCDU/|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-6|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-7|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-8|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-9|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-10|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-11|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-12|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-13|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-14|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-15|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-16|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-17|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-18|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-19|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-20|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-21|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-22|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-23|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-24|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-25|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-26|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-27|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-28|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-29|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-30|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-31|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-32|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-33|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-34|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-35|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-36|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-37|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-38|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-39|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-40|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-41|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-42|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-43|18|450|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-44|18|498|Other deterministic changes|Whole body|MCDU/|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-45|18|572|Other deterministic changes|Whole body|MCDU/|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-46|18|577|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-47|18|577|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-48|18|577|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-49|18|584|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-50|18|584|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-51|18|584|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-52|18|584|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-53|18|584|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-54|18|584|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-55|18|584|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-56|18|584|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-57|18|584|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-58|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-59|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-60|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-61|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-62|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-63|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-64|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-65|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-66|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-67|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-68|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-69|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-70|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-71|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-72|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-73|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-74|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-75|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-76|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-77|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-78|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-79|18|591|n/a|n/a|n/a|
1003-21-18|n/a,S6|1|100|neutrons fission|0.6|grays|External exposure|code S6 1 fraction 20 m|80 (80 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-18-80|18|591|n/a|n/a|n/a|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-1|19|278|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF FEMUR TO LIVER.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-2|19|383|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ trigeminal nerve (differentiated ganglioneuroblastoma).,MPATH: 437 - neurofibrosarcoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-3|19|394|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ cecum.,MPATH: 218 - neoplasm|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-4|19|395|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tcvs to muscle of tail.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-5|19|409|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-6|19|411|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-7|19|428|n/a|n/a|n/a|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-8|19|471|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-9|19|479|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXUO/ pylorus--sarcomatous.,MPATH: 218 - neoplasm|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-10|19|519|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-11|19|540|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-12|19|548|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ bile duct.,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-13|19|571|n/a|n/a|n/a|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-14|19|599|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-15|19|605|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-16|19|613|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-17|19|614|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS TO FEMORAL MUSCLE.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-18|19|615|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF FEMUR TO LIVER.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-19|19|638|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ORBITAL MUSCLES.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-20|19|642|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-21|19|645|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-22|19|660|n/a|n/a|n/a|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-23|19|661|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-24|19|681|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-25|19|691|Neoplasia benign|Bloodvessels among cardiovascular system|TCVO/ abdom. wall. Metastases Lung|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-26|19|696|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-27|19|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-28|19|701|Other deterministic changes|Whole body|MCDU/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-29|19|708|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-30|19|715|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWX: TXAS METAS. FROM SALIV. GL. TO LUNG.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-31|19|741|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thorax with invas. into ribs & vert.. Muscle|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-32|19|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-33|19|744|n/a|n/a|n/a|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-34|19|749|n/a|n/a|n/a|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-35|19|751|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-36|19|753|n/a|n/a|n/a|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-37|19|758|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcutis of skin over testis with invas. of femur muscle..|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-38|19|768|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-39|19|778|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-40|19|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-41|19|786|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-42|19|789|Other deterministic changes|Whole body|MCDU/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-43|19|790|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ORBITAL MUSCLES.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-44|19|793|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ anus infiltr. tail bone & rectal muscle wall. Metastases  Muscle tcfs to skeletal muscle around anus.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-45|19|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Skin tcfs to skin of anal region.,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-46|19|800|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases  tbos of femur to visc. & pariet. peritoneum. Metastases  Kidney tbos of femur to kidney. Metastases  Muscle tbos of femur to muscle of thigh. Metastases Liver Metastases  GI tract tbos of femur to esophagus.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-47|19|802|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Liver Metastases Lung Metastases  tkac to parietal mesen, surface of pancr. & visc. perit..,MPATH: 549 - carcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-48|19|802|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ stomach.,MPATH: 549 - carcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-49|19|804|n/a|n/a|n/a|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-50|19|807|Inflammation and/or fibrotic diseases|Integumentary system|MSDA/  acute|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-51|19|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-52|19|830|Other deterministic changes|Whole body|MCDU/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-53|19|835|n/a|n/a|n/a|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-54|19|837|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ dorsal thoracic reg..|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-55|19|838|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-56|19|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-57|19|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to intercostal muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-58|19|851|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO CHEEK MUSCLE.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-59|19|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-60|19|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-61|19|853|Other deterministic changes|Whole body|MCDU/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-62|19|856|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-63|19|856|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-64|19|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-65|19|862|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-66|19|863|Neoplasia unclassified|Kidney among urinary system diseases,MA: 0000368 - kidney|TKTC/  Transitional cells,MPATH: 218 - neoplasm|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-67|19|863|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ mixed sal. gl. t..,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-68|19|868|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac to cheek muscle.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-69|19|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-70|19|871|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-71|19|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-72|19|880|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ epitheliomatous in throat region with metas. to lung & pt and br l.n..|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-73|19|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-74|19|883|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ mixed carcinoma-periurethral. Metastases  Lung txac, mixed carcinoma, to lung.,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-75|19|883|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ colon.,MPATH: 551 - sarcoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-76|19|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-77|19|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-78|19|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-79|19|914|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-80|19|922|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-81|19|932|Other deterministic changes|Whole body|MCDU/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-82|19|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-83|19|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-84|19|936|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-85|19|939|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-86|19|939|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-87|19|942|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-88|19|945|Other deterministic changes|Whole body|MCDU/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-89|19|945|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-90|19|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-91|19|947|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-92|19|952|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-93|19|963|n/a|n/a|n/a|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-94|19|970|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum.Enteritis acute,MPATH: 212 - inflammation|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-95|19|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-96|19|976|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-97|19|981|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/ region involv. prepuce, testis and epididymis.Testis|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-98|19|991|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-99|19|999|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-100|19|1006|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-101|19|1016|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-102|19|1019|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-103|19|1031|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-104|19|1044|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-105|19|1045|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ between scapulae. Metastases Lung|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-106|19|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-107|19|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-108|19|1074|Other deterministic changes|Whole body|MCDU/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-109|19|1095|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-110|19|1096|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-111|19|1099|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-112|19|1100|Other deterministic changes|Whole body|MCDU/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-113|19|1102|Other deterministic changes|Whole body|MCDU/|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-114|19|1115|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ saliv. gl. Metastases  Lung txas metas. from saliv. gl. to lung.,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-115|19|1120|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tgac to orbital muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-116|19|1129|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-117|19|1157|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ distal end of femur. Metastases  Muscle tbos to femoral muscle.|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-118|19|1160|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-119|19|1174|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-19|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|120 records survival 719± 18 lifespan study|1003-21-19-120|19|1254|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-1|20|256|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal Metastases  tmab on visceral perit. of spleen, kid., & adrenal.,MPATH: 218 - neoplasm|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-2|20|287|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-3|20|291|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-4|20|359|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-5|20|369|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-6|20|385|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-7|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-8|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-9|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-10|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-11|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-12|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-13|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-14|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-15|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-16|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-17|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-18|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-19|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-20|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-21|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-22|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-23|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-24|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-25|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-26|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-27|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-28|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-29|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-30|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-31|20|450|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-32|20|482|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-33|20|577|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-34|20|577|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-35|20|577|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-36|20|577|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-37|20|577|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-38|20|582|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-39|20|584|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-40|20|584|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-41|20|584|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-42|20|584|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-43|20|584|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-44|20|584|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-45|20|584|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-46|20|584|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-47|20|584|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-48|20|584|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-49|20|591|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWM: TMAB ON VISCERAL PERIT. OF SPLEEN, KID., & ADRENAL.|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-50|20|591|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-51|20|591|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-52|20|591|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-53|20|591|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-54|20|591|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-55|20|591|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWM: TMAB ON VISCERAL PERIT. OF SPLEEN, KID., & ADRENAL.|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-56|20|591|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWM: TMAB ON VISCERAL PERIT. OF SPLEEN, KID., & ADRENAL.|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-57|20|591|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-58|20|591|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-59|20|591|n/a|n/a|n/a|
1003-21-20|n/a,S7|1|100|neutrons fission|1.2|grays|External exposure|code S7 1 fraction 20 m|60 (60 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|7 records lifespan study females before or after 500 d after exposure|1003-21-20-60|20|591|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWM: TMAB ON VISCERAL PERIT. OF SPLEEN, KID., & ADRENAL.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-1|21|100|n/a|n/a|n/a|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-2|21|288|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWP: TPAC TO CEREBRUM.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-3|21|291|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWK: TKAC TO VISCERAL PERITONEUM.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-4|21|344|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-5|21|365|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-6|21|393|Other deterministic changes|Whole body|MCDU/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-7|21|408|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-8|21|425|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-9|21|456|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-10|21|477|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-11|21|509|Neoplasia unclassified|Central nervous system among nervous system|TNNB/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-12|21|543|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-13|21|551|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-14|21|554|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC L.N..|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-15|21|562|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWG: TGAC TO BRAIN.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-16|21|580|Other deterministic changes|Whole body|MCDU/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-17|21|603|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to muscle of rib cage.,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-18|21|621|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ORBITAL MUSCLE.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-19|21|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-20|21|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-21|21|666|Other deterministic changes|Whole body|MCDU/ Eyes missing|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-22|21|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-23|21|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-24|21|683|n/a|n/a|n/a|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-25|21|690|Other deterministic changes|Whole body|MCDU/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-26|21|692|Other deterministic changes|Whole body|MCDU/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-27|21|708|Other deterministic changes|Whole body|MCDU/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-28|21|711|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-29|21|712|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-30|21|718|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-31|21|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-32|21|729|n/a|n/a|n/a|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-33|21|729|n/a|n/a|n/a|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-34|21|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-35|21|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-36|21|743|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ORBITAL MUSCLE.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-37|21|749|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-38|21|752|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-39|21|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-40|21|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-41|21|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-42|21|778|n/a|n/a|n/a|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-43|21|782|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-44|21|787|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenum.,  Head/neck missing, eyes missing,MPATH: 218 - neoplasm|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-45|21|788|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-46|21|806|n/a|n/a|n/a|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-47|21|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-48|21|808|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-49|21|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-50|21|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-51|21|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-52|21|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-53|21|823|Neoplasia malignant|Endocrine system|TGAC/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-54|21|829|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-55|21|829|n/a|n/a|n/a|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-56|21|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-57|21|841|n/a|n/a|n/a|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-58|21|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-59|21|843|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ jejunum.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-60|21|844|Other deterministic changes|Whole body|MCDU/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-61|21|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tgac to muscle of face.,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-62|21|850|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-63|21|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-64|21|855|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWK: TKAC TO VISCERAL PERITONEUM.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-65|21|863|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  trac to mediastinum, visc. and pariet. pleura. Metastases  Lymphoret.System trac to l.n.,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-66|21|874|n/a|n/a|n/a|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-67|21|875|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  Muscle trac to intercostal muscle. Metastases  trac to pleura, rib cage.,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-68|21|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-69|21|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-70|21|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-71|21|880|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-72|21|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-73|21|896|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-74|21|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-75|21|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-76|21|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-77|21|907|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-78|21|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-79|21|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-80|21|918|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO CN L.N.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-81|21|920|n/a|n/a|n/a|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-82|21|925|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-83|21|926|Other deterministic changes|Whole body|MCDU/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-84|21|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-85|21|941|Neoplasia malignant|Endocrine system|TGAC/   Metastases  tgac to brain.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-86|21|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-87|21|945|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma Metastases  tpac to cerebrum.,MPATH: 218 - neoplasm|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-88|21|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  tkac to visceral peritoneum.,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-89|21|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-90|21|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-91|21|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-92|21|967|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ base of tail.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-93|21|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-94|21|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-95|21|970|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ colon. Metastases  Kidney tiac of colon to kidney. Metastases  Lymphoret.System tiac of colon to mn. l.n. and spleen. Metastases  tiac of colon to viscera and peritoneum. Metastases Liver,MPATH: 218 - neoplasm|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-96|21|971|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tgac to orbital muscle.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-97|21|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-98|21|974|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ prostate.,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-99|21|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lymphoret.System trac to parathymic l.n..,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-100|21|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-101|21|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-102|21|981|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to cn l.n. Metastases  Muscle tgac to skull muscle & skin. Metastases Lung|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-103|21|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-104|21|986|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-105|21|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-106|21|1005|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcutis of neck.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-107|21|1027|Other deterministic changes|Whole body|MCDU/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-108|21|1033|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-109|21|1061|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-110|21|1063|Other deterministic changes|Whole body|MCDU/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-111|21|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-112|21|1105|Neoplasia unclassified|Other local manifestations and miscellaneus|THWI: TIAC OF COLON TO LIVER.|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-113|21|1116|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-114|21|1121|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus.,MPATH: 218 - neoplasm|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-115|21|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-116|21|1135|Other deterministic changes|Whole body|MCDU/|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-117|21|1161|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-118|21|1220|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-119|21|1255|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-21|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|119 records survival 714± 18 lifespan study|1003-21-21-120|21|1258|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-1|22|263|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-2|22|298|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-3|22|298|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-4|22|332|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ with extens. to adnexal tissue of adr. and kid..,MPATH: 242 - hemangiosarcoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-5|22|340|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-6|22|356|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-7|22|400|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-8|22|435|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-9|22|465|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-10|22|472|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-11|22|484|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-12|22|536|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-13|22|543|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ tongue.,MPATH: 549 - carcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-14|22|547|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-15|22|547|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS TO MUSCLES OF THORAX.|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-16|22|558|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-17|22|565|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-18|22|565|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS TO MUSCLE AT TAIL BASE.|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-19|22|572|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-20|22|584|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-21|22|589|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-22|22|592|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-23|22|599|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-24|22|603|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: MUSCLE INVASION BY TCFS OF LOWER JAW.|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-25|22|610|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-26|22|611|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-27|22|617|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS TO MUSCLES OF THORAX.|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-28|22|624|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-29|22|624|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-30|22|629|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-31|22|631|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-32|22|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-33|22|640|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-34|22|658|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-35|22|666|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-36|22|677|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-37|22|687|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-38|22|688|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-39|22|694|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-40|22|701|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-41|22|710|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-42|22|711|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-43|22|714|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-44|22|720|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-45|22|725|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/   Metastases Lung Metastases Liver,MPATH: 549 - carcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-46|22|726|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-47|22|728|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-48|22|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-49|22|732|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-50|22|733|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-51|22|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-52|22|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-53|22|744|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MNIA/ thalamus.|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-54|22|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-55|22|754|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWC: TCFS OF RIBS - L.N NOT STATED.|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-56|22|759|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-57|22|763|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS TO MUSCLE OF FOREARM.|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-58|22|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-59|22|771|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-60|22|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-61|22|780|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-62|22|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-63|22|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-64|22|785|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ forearm. Metastases  Muscle tbos to muscle of forearm. Metastases Lung|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-65|22|785|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-66|22|790|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ lower jaw. Metastases  Skin skin invasion by tcfs. Metastases  Muscle muscle invasion by tcfs of lower jaw.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-67|22|793|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/ bilateral.|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-68|22|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-69|22|799|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-70|22|800|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-71|22|805|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-72|22|810|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-73|22|813|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|TMAT/   Metastases Lung tmat (mam. t.) to lung.,MPATH: 255 - adenoacanthoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-74|22|815|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-75|22|817|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-76|22|821|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-77|22|833|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-78|22|834|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Muscle tgac to muscle of skull.|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-79|22|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-80|22|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-81|22|850|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-82|22|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-83|22|859|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-84|22|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-85|22|866|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/ Eyes missing|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-86|22|870|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-87|22|870|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-88|22|872|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-89|22|875|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: MUSCLE INVASION BY TCFS OF LOWER JAW.|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-90|22|876|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-91|22|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-92|22|891|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/  ,MPATH: 551 - sarcoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-93|22|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-94|22|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-95|22|911|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-96|22|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-97|22|920|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/ mult. metas. incl. spleen and visc. peritoneum. Metastases Lung Metastases Liver,MPATH: 549 - carcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-98|22|930|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-99|22|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-100|22|934|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-101|22|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-102|22|935|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-103|22|936|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ surrounding ribs. Metastases  Lymphoret.System tcfs of ribs - l.n not stated.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-104|22|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-105|22|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tcfs to muscle at tail base.,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-106|22|964|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-107|22|981|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-108|22|992|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  Muscle tcvs to muscle of thigh. Metastases  Skin tcvs to skin of thigh.,MPATH: 242 - hemangiosarcoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-109|22|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-110|22|995|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-111|22|997|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-112|22|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-113|22|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-114|22|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-115|22|1053|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCA/ MMCA/ MMCA/ MMCA/  acute,MPATH: 212 - inflammation|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-116|22|1054|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-117|22|1079|n/a|n/a|n/a|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-118|22|1091|Other deterministic changes|Whole body|MCDU/|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-119|22|1095|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ thorax. Metastases  Muscle tcfs to muscles of thorax.,MPATH: 408 - soft tissue fibrosarcoma|
1003-21-22|n/a,S8|1|100|neutrons fission|1.6|grays|External exposure|code S8 1 fraction 20 m|120 (120 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 646± 17 lifespan study|1003-21-22-120|22|1134|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-1|23|379|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-2|23|406|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-3|23|411|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-4|23|534|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-5|23|552|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-6|23|559|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-7|23|596|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-8|23|609|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-9|23|611|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-10|23|618|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-11|23|645|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-12|23|653|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-13|23|659|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-14|23|670|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-15|23|674|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-16|23|690|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-17|23|705|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-18|23|712|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-19|23|733|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-20|23|736|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-21|23|758|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-22|23|808|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-23|23|820|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-24|23|824|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-25|23|831|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-26|23|837|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-27|23|845|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-28|23|849|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-29|23|852|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-30|23|856|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-31|23|862|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-32|23|865|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-33|23|865|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-34|23|874|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-35|23|879|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-36|23|886|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-37|23|900|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-38|23|913|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-39|23|918|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-40|23|919|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-41|23|919|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-42|23|948|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-43|23|953|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-44|23|975|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-45|23|976|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-46|23|985|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-47|23|985|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-48|23|1025|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-49|23|1095|n/a|n/a|n/a|
1003-21-23|n/a,SL|1|100|neutrons fission|2.4|grays|External exposure|code SL 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|50 records survival 678± 25 lifespan study|1003-21-23-50|23|1190|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-1|24|198|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-2|24|198|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-3|24|198|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-4|24|198|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-5|24|198|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-6|24|338|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-7|24|464|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-8|24|580|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-9|24|593|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-10|24|609|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-11|24|610|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-12|24|613|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-13|24|646|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-14|24|653|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-15|24|653|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-16|24|664|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-17|24|671|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-18|24|691|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-19|24|701|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-20|24|747|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-21|24|759|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-22|24|766|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-23|24|766|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-24|24|771|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-25|24|777|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-26|24|785|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-27|24|808|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-28|24|835|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-29|24|844|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-30|24|851|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-31|24|863|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-32|24|866|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-33|24|887|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-34|24|912|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-35|24|915|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-36|24|915|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-37|24|926|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-38|24|928|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-39|24|945|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-40|24|946|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-41|24|947|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-42|24|957|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-43|24|978|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-44|24|1009|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-45|24|1011|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-46|24|1038|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-47|24|1041|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-48|24|1050|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-49|24|1058|n/a|n/a|n/a|
1003-21-24|n/a,SH|1|100|neutrons fission|2.4|grays|External exposure|code SH 1 fraction 20 m|50 (50 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|45 records survival 702 ± 25 lifespan study|1003-21-24-50|24|1072|n/a|n/a|n/a|
